Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease
Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease
Active, not recruiting · NCT05243017 · Registry updated 2025-03-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-03-10 | NCT05243017 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| UniQure Biopharma B.V. | 5 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cardiff University | Cardiff | United Kingdom | 4 |
| Instytut Psychiatrii i Neurologii | Warsaw | Poland | 1 |
| Interventional Neuro Center | Warsaw | Poland | 1 |
| National Hospital for Neurology & Neurosurgery | London | United Kingdom | 3 |